These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 33902368)

  • 1. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment.
    Patterson BJ; Myers K; Stewart A; Mange B; Hillson EM; Poulos C
    Expert Rev Vaccines; 2021 Jun; 20(6):729-741. PubMed ID: 33902368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization funding across 28 European countries.
    Faivre P; Benčina G; Campbell R; Quilici S; Dauby N; Tešović G; Bonanni P; Drury R
    Expert Rev Vaccines; 2021 Jun; 20(6):639-647. PubMed ID: 33759675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferences and Willingness to Pay for Herpes Zoster Vaccination Among Chinese Adults: Discrete Choice Experiment.
    Xia Y; Wang M; Hu M; Wang Y; Yuan B; Zhu D; He P
    JMIR Public Health Surveill; 2024 Aug; 10():e51242. PubMed ID: 39121469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
    Safonova E; Yawn BP; Welte T; Wang C
    Respir Res; 2023 Jan; 24(1):35. PubMed ID: 36709298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
    Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
    J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shingles vaccination uptake in Massachusetts adults aged 50 years and older.
    Draper M; Stergiopoulos S
    Vaccine; 2021 Nov; 39(46):6781-6786. PubMed ID: 34625290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing herpes zoster vaccination among older people in China: results from a discrete choice experiment.
    Zhang H; Zhang LR; Chu LC; Sun X; Jiang XW
    Public Health; 2023 Jul; 220():33-34. PubMed ID: 37263175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
    Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
    Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
    Lu PJ; Euler GL; Jumaan AO; Harpaz R
    Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic literature review to assess the burden of herpes zoster disease in China.
    Yin D; Van Oorschot D; Jiang N; Marijam A; Saha D; Wu Z; Tang H; Diaz-Decaro J; Watson P; Xie X; Ren Y; He Y; Feng Y
    Expert Rev Anti Infect Ther; 2021 Feb; 19(2):165-179. PubMed ID: 32997550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Willingness to Vaccinate Against Herpes Zoster and Its Associated Factors Across WHO Regions: Global Systematic Review and Meta-Analysis.
    Wang Q; Yang L; Li L; Liu C; Jin H; Lin L
    JMIR Public Health Surveill; 2023 Mar; 9():e43893. PubMed ID: 36892937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community and patient values for preventing herpes zoster.
    Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
    Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    Le P; Rothberg MB
    JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.
    Litt J; Cunningham AL; Arnalich-Montiel F; Parikh R
    Infect Dis Ther; 2024 Jul; 13(7):1439-1459. PubMed ID: 38834857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.